The eosinophil is well recognized as a central effector cell in the inflamed asthmatic airway. Eosinophils release toxic basic proteins and lipid mediators such as cysteinyl-leukotrienes that cause bronchial epithelial damage and airflow obstruction. Eosinophil-selective cytokines and chemokine including interleukin (IL)-5, eotaxin and RANTES may represent targets for novel asthma therapies.
Related Journals of Eosinophilic Inflammation
Archives of inflammation, Immunogenetics: Open Access, Infectious Diseases & Therapy, Immunome Research, Immunome Research, Immunology, Immunology and Allergy Clinics of North America, Journal of Allergy and Asthma, Immunopharmacology and Immunotoxicology, Indian Journal of Allergy Asthma and Immunology
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2018 All rights reserved. iMedPub LTD Last revised : August 20, 2018